AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 82 min read$BBIO

Kumar Neil sold $5.4M of BBIO (indirect holdings)

Kumar Neil (Chief Executive Officer) sold 80,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $67.67 ($65.72–$68.96, $5.41M total) across 14 trades over 2026-06-04 to 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Jun 8, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale totaling $5.41M across 80,000 shares, executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

This provides fresh, primary-source information on insider activity, but the 10b5-1 structure typically limits interpretive impact.

03

What to watch

The filing shows indirect ownership and multiple small trades across two days; traders may focus on whether future filings show continued selling or a shift to buying.

Relevance 5/10Novelty 8/10Timing: Filed June 8, 2026 (covers sales June 4–5)

Background

The article is an SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc. (BBIO).

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio CEO Kumar Neil sold $5.41M of BBIO shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction may be muted given the pre-arranged nature.

Evidence & confidence

The filing is a primary-source Form 4 showing sale size ($5.41M) and that it was executed under a Rule 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity planning rather than a change in fundamentals.

Key entities

  • issuer
    BridgeBio Pharma, Inc.

    Company whose shares were sold by its CEO under a 10b5-1 plan.

  • insider
    Kumar Neil

    CEO and director who sold 80,000 shares of BBIO for ~$5.41M.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

OCT 7
$BBIOMedAI 9/10

BridgeBio Pharma stock rating reiterated at Buy by Canaccord

Canaccord reiterated a Buy rating and $106 price target for BridgeBio Pharma (BBIO) after positive cardiac data from its LGMD2I/R9 treatment program. The company's stock trades at $66.96, below the target. Analysts maintain a Strong Buy consensus with targets ranging from $80 to $156. BridgeBio estimates a 90% success probability and peak sales of $1.3B by 2034 for the treatment.

investing.com2 min
OCT 6
$BBIOHigh

FDA Accepts BridgeBio's Infigratinib NDA For Priority Review

BridgeBio Pharma (BBIO) announced the FDA accepted its NDA for infigratinib to treat achondroplasia in children, granting Priority Review. The PDUFA target date is February 4, 2027. The NDA is backed by positive Phase 3 study results showing significant improvements in height velocity and body proportionality. BBIO shares rose 1.65% on Friday and are up 3.42% in premarket trading.

rttnews.com2 min
OCT 6
$BBIOHigh

H.C. Wainwright reiterates Buy on BridgeBio stock, cites cardiac data

H.C. Wainwright reiterated a Buy rating and $120 price target on BridgeBio Pharma (BBIO) after positive cardiac data from its muscular dystrophy treatment. The stock is currently at $66.14, with analysts maintaining a Strong Buy consensus and targets ranging from $80 to $157. BridgeBio reported 202% revenue growth and 94% gross margins over the last year, according to InvestingPro.

investing.com1 min
OCT 6
$BBIOMed

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio Pharma (BBIO) announced FDA acceptance of its NDA for oral infigratinib to treat children with achondroplasia, with a Priority Review and PDUFA target date of February 4, 2027. The PROPEL 3 trial met primary and key secondary endpoints, showing significant improvements in height velocity and body proportionality. If approved, it would be the first oral therapy for this condition.

globenewswire.com3 min